KalVista Pharmaceuticals, Inc. (KALV)
$27.00+0.00%Close
BUYBULL · day 32
Key stats
- Market cap
- $1.4B
- Beta
- -0.29
- P/E (TTM)
- -8.36
- 1W
- +0.19%
- 1M
- +0.75%
- vs SPY 1W
- +0.32%
- vs SPY 1M
- -1.76%
Industry peers
FMP comparable companies · ranked by market cap
- KRYSSELLKrystal Biotech, Inc.$9.5BBEARQ 46$321.16-3.29%
- PTGXSELLProtagonist Therapeutics, Inc.$8.9BRECOVERYQ 32$138.49-4.41%
- KNSABUYKiniksa Pharmaceuticals International, plc$6.0BBULLQ 23$78.53-0.90%
- SRRKSELLScholar Rock Holding Corporation$4.9BCRISISQ 22$40.52-3.39%
- COGTSELLCogent Biosciences, Inc.$4.8BCRISISQ 12$28.09-5.67%
- KURASELLKura Oncology, Inc.$873MCRISISQ 12$9.83-5.48%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
ANALYST & RATINGS
LOADING…Loading analyst data…
Company news
Loading headlines…
FAQ
- What is LOPJLB’s current signal on KALV?
- LOPJLB’s latest quantitative signal on KalVista Pharmaceuticals, Inc. (KALV) is BUY in a BULL regime. Signals are updated daily.
- What market regime is KALV in?
- KalVista Pharmaceuticals, Inc. (KALV) is currently classified in the BULL HMM market regime on LOPJLB.
- What does KalVista Pharmaceuticals, Inc. (KALV) do?
- KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: Sebetralstat for HAE and Factor XIIa. The company was founded by T. Andrew Croc…